Panacea Venture

Panacea Venture is a venture capital firm established in 2017 and located in Silicon Valley, California. The firm specializes in healthcare and life sciences, focusing on early-stage investments and incubation of innovative companies within these sectors. Through its various funds, Panacea Venture aims to support the growth of transformative healthcare solutions and advancements in life sciences.

Andrew Aherrera MD

Partner

Michelle Chung

Venture Partner

Katherine Cohen

Venture Partner

Nancy Donahue

Venture Partner

Hai Mi Ph.D

Founding Managing Partner and Venture Partner

Winson Tang

Venture Partner

Debra Yu

Partner and COO

Nikki Zhang

Partner

Jeffry Wu Ph.D

Partner

Fay Xing Ph.D

Partner

39 past transactions

VelaVigo

Seed Round in 2024
VelaVigo is a start-up company engaged in macromolecular biopharmaceuticals.

Human Longevity

Series B in 2024
Human Longevity (HLI) is a genomic-based health intelligence company focused on proactive healthcare and enhancing quality of life. Founded in 2013 and headquartered in San Diego, California, HLI utilizes a comprehensive database of genomic and phenotypic data, combined with advanced machine learning techniques, to drive medical discoveries and transform healthcare practices. The company operates multiple business areas, including the HLI Health Nucleus, a clinical research center that employs whole-genome sequencing, advanced imaging, and curated personal health data to provide an in-depth understanding of individual health. HLI's platform also addresses age-related decline in stem cell function and focuses on major health issues such as cancer, diabetes, obesity, heart and liver diseases, and dementia. By integrating DNA sequencing with expert analysis, HLI aims to empower individuals to take control of their health and shift medical care from a reactive to a proactive approach.

CASI Pharmaceuticals

Post in 2024
CASI Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics, particularly in the fields of hematology and oncology. The company focuses on addressing unmet medical needs by acquiring and advancing various pharmaceutical products. Among its offerings, EVOMELA is notable for its role as a conditioning treatment prior to autologous stem cell transplants in multiple myeloma patients, while its portfolio also includes CID-103, CNCT19, MARQIBO, ZEVALIN, and ENMD-2076. CASI Pharmaceuticals primarily generates revenue through the sales of EVOMELA, and it aims to establish itself as a leader in the biopharmaceutical sector by leveraging its expertise in drug development and regulatory processes, particularly in the China market.

Eos BioInnovation

Seed Round in 2024
Eos BioInnovation is an investment firm focused on launching and building start-ups in the field of regenerative medicine. The company specializes in incubating, launching, and developing early-stage companies that emerge from leading academic labs and research institutions. By supporting these ventures, Eos BioInnovation aims to transform innovation in regenerative medicine and enable clients to achieve a strong track record of success.

Actym Therapeutics

Series A in 2023
Actym Therapeutics is a biotechnology company based in Berkeley, California, dedicated to developing innovative immuno-oncology therapies for cancer treatment. Founded in 2017, the company has created a unique therapeutic platform known as STACT (S. Typhimurium-Attenuated Cancer Therapy), which uses an attenuated microbial approach to target solid tumors while sparing healthy tissue. This platform allows for the delivery of multiple immuno-modulatory payloads directly to immune cells residing within tumors, addressing challenges faced by traditional therapies. In preclinical studies, STACT has shown promise in enhancing treatment efficacy by engaging various biological pathways from a single therapy. The company successfully secured $34 million in a Series A financing round in April 2020, which was co-led by prominent venture funds, highlighting its potential in the biopharmaceutical landscape.

Chime Biologics

Series B in 2023
Chime Biologics Limited is a Contract Development and Manufacturing Organization (CDMO) based in Wuhan, China, established in 2013. The company specializes in providing a comprehensive range of biopharmaceutical development and manufacturing services, including drug substance and drug product manufacturing, cell line development, and protein science characterization. Chime Biologics also offers technical transfer, regulatory support, and project management services to meet the needs of the biopharmaceutical industry. The organization supports clients through all stages of development, from early drug development to late-stage clinical trials and commercial production, ensuring compliance with cGMP standards. By delivering customer-centric and cost-effective solutions, Chime Biologics aims to enhance access to affordable medicines and improve patient care.

Base Therapeutics

Series A in 2023
Base Therapeutics is a biotechnology company focused on developing cell and gene editing technologies aimed at treating cancerous diseases. Its core innovation includes a natural killer cell genetic engineering platform, along with various cell therapy products specifically designed for the treatment of lung cancer, liver cancer, glioma, and other hematological tumors. By enhancing the safety and effectiveness of clinical applications of gene editing, Base Therapeutics aims to provide healthcare professionals with advanced therapeutic options for patients suffering from these challenging conditions.

NewAmsterdam Pharma Company

Post in 2022
NewAmsterdam Pharma is a clinical-stage biopharmaceutical company dedicated to the research and development of innovative therapies for cardio-metabolic diseases. The company aims to enhance patient care for those suffering from metabolic conditions where existing treatments are insufficient or poorly tolerated. Its lead product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor designed to address the shortcomings of current LDL-C lowering therapies. Through its focus on transformative solutions, NewAmsterdam Pharma seeks to make a significant impact in the management of cardio-metabolic diseases.

Coastar Therapeutics

Seed Round in 2022
Coastar Therapeutics is a biotechnology company based in San Diego, California, focused on developing a novel drug delivery platform that utilizes erythrocyte enveloped virus technology. This platform is designed for repeated dosing of oncolytic viruses while evading the immune system's recognition and response, which is a common challenge in systemic drug therapies. By employing human cell lipids with self-identifying motifs, Coastar's technology protects the therapeutic virus from neutralizing antibodies and immune cells, ensuring effective delivery to tumor sites for cancer treatment and immunotherapy. Founded in 2017, the company is also working on expanding its ELCV solutions to address other therapeutic areas, while its unique process technology offers advantages in mass production and cost efficiency.

Jade Biomedical

Series B in 2022
Jade Biomedical offers regulatory and analytical testing services to biopharmaceutical companies globally. As the first registered biologics contract organization, Bio-CQOR, it provides comprehensive quality management solutions tailored to the needs of the biopharmaceutical sector. The company specializes in contract quality management, GMP testing, technical contracting, and inspection services. Its leadership team possesses extensive experience with various drug agencies, including NMPA, FDA, EMA, PMDA, and PICS, ensuring a deep understanding of regulatory requirements. Jade Biomedical's expertise spans multiple therapeutic platforms, including monoclonal antibodies, antibody-drug conjugates, and cell and gene therapies, reinforcing its capability to support clients throughout the drug development lifecycle.

HanchorBio

Series A in 2022
HanchorBio is a biotechnology research firm focused on developing innovative treatments for cancer. The company specializes in drug discovery that leverages tumor immunology, aiming to enhance the quality of life for cancer patients. By concentrating on cutting-edge research and development, HanchorBio seeks to revolutionize cancer treatment through its commitment to advancing therapeutic options.

Fineimmu

Seed Round in 2022
Fineimmu specializes in the development of innovative cell therapy drugs and immunodiagnostic products aimed at improving cancer treatment. The company's technology is centered on individualized tumor immunotherapy and immunodiagnostics, enabling healthcare professionals to assess the anti-tumor immune function of key proteins like PD-1 and PD-L1. Fineimmu's approach also includes precise combination therapies and rapid efficacy assessments, which together contribute to effective treatment systems for patients with common malignant tumors. The company aims to enhance therapeutic outcomes through personalized medicine, addressing the unique needs of each patient.

Domain Therapeutics

Series A in 2022
Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G protein-coupled receptors (GPCRs), which are key drug targets in various diseases. Founded in 2001, the company specializes in developing small molecules for the treatment of central nervous system (CNS) disorders and cancer. It employs its proprietary technology platform, DTect-All, which enables the identification of orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs) that are challenging to discover using conventional methods. In addition, Domain Therapeutics offers BioSens-All, a platform to explore the signaling complexities associated with GPCR activation, enhancing its ability to address difficult targets, such as orphan and peptidic GPCRs.

GT Apeiron Therapeutics

Series A in 2022
GT Apeiron Therapeutics is a developer of innovative drugs utilizing artificial intelligence technology. The company develops breakthrough investigational medicines by harnessing the power of artificial intelligence, aiming to drastically increase efficiency throughout the drug discovery process.

Harvest Integrated Research Organization

Series A in 2022
Harvest Integrated Research Organization (HiRO) is an innovative clinical research organization (CRO) with a global presence. It offers a comprehensive suite of services tailored for biotechnology and pharmaceutical companies, including pre-clinical strategic planning, clinical trial design, regulatory affairs, pharmacovigilance, statistics, data management, and end-to-end project management. HiRO is committed to facilitating the transition of pharmaceutical products from the laboratory to the market, collaborating closely with its clients to develop more effective and cost-efficient therapies for patients worldwide. As an emerging leader in the CRO sector, HiRO aims to enhance the drug development process through its integrated capabilities and dedication to quality.

Day Zero Diagnostics

Venture Round in 2022
Day Zero Diagnostics Inc. is an infectious disease diagnostics company focused on developing rapid, sequencing-based diagnostics that identify bacterial pathogens and their antibiotic resistance profiles. The company employs advanced technologies such as Blood2Bac, which enhances bacterial DNA recovery from clinical samples, and BacDetect, designed for the swift detection of bacterial DNA. Its Keynome ID algorithm classifies bacterial species, while Keynome g-AST utilizes machine learning for genomic antibiotic susceptibility testing. Additionally, Day Zero maintains MicrohmDB, a comprehensive database that integrates whole genome sequencing data with resistance and susceptibility profiles of clinically relevant pathogens. Founded in 2016 and based in Boston, Massachusetts, Day Zero aims to transform infectious disease diagnostics by providing complete diagnoses—including species identification and antibiotic resistance—within hours, significantly improving treatment outcomes and reducing costs associated with prolonged diagnostic processes.

St Phi Therapeutics

Series A in 2022
Yizun Biotechnology is a cutting-edge immune cell therapy company that has developed many unique platform technologies, including solid tumor treatment and allogeneic universal cell therapy.

Tailai Biosciences

Venture Round in 2022
TaiLai Biosciences is a biotechnology company based in Shanghai, China, focused on advancing cancer research through its proprietary multiomics technology. The company specializes in developing non-invasive cancer screening and analysis methods, which facilitate a deeper understanding of cancer development and aid in the creation of immune-guided therapies. TaiLai Biosciences offers a range of biopsy products and services that leverage extensive biological data, including DNA, RNA, proteins, and metabolic small molecules. By utilizing bioinformatics and computational science, the company aims to uncover correlations within this complex biological information, ultimately enhancing the effectiveness of cancer diagnosis and treatment.

VelaVigo

Angel Round in 2021
VelaVigo is a start-up company engaged in macromolecular biopharmaceuticals.

TriArm Therapeutics

Venture Round in 2021
TriArm Therapeutics is a cell therapy company established by Panacea Venture, with research and development operations in Germany, the United States, and the Greater China region. The company specializes in the research and clinical development of CD19 CAR-T products, utilizing non-viral gene transfer technology. This innovative approach significantly lowers both the cost and preparation time associated with cell therapy products, ultimately aiming to enhance therapeutic outcomes for cancer patients.

Inmagene Biopharmaceuticals

Series C in 2021
Inmagene Biopharmaceuticals Co. Ltd. is a Shanghai-based biopharmaceutical company founded in 2019, specializing in the research and pre-clinical development of therapies for immunology-related diseases. The company focuses on creating innovative drug candidates that address unmet medical needs globally, employing a strategy known as "Borderless Innovation." Inmagene has developed a diverse pipeline, including IMG-020, a protein drug designed to target IL-17A, which utilizes a combination of Affibody's protein therapeutics platform and Albumod technology to enhance potency and extend half-life. In addition to IMG-020, the company boasts several clinical-stage assets and multiple preclinical candidates aimed at improving pharmacokinetic and pharmacodynamic properties, safety profiles, and dosing convenience for patients. With additional offices in Hangzhou and Beijing, Inmagene is dedicated to advancing drug development through cutting-edge technology and a commitment to global collaboration in the fight against immunological diseases.

Chime Biologics

Series A in 2021
Chime Biologics Limited is a Contract Development and Manufacturing Organization (CDMO) based in Wuhan, China, established in 2013. The company specializes in providing a comprehensive range of biopharmaceutical development and manufacturing services, including drug substance and drug product manufacturing, cell line development, and protein science characterization. Chime Biologics also offers technical transfer, regulatory support, and project management services to meet the needs of the biopharmaceutical industry. The organization supports clients through all stages of development, from early drug development to late-stage clinical trials and commercial production, ensuring compliance with cGMP standards. By delivering customer-centric and cost-effective solutions, Chime Biologics aims to enhance access to affordable medicines and improve patient care.

Maestro Surgical

Seed Round in 2021
Maestro Surgical is a platform for medical surgical robotics technology.

Real Star Rehabilitation

Venture Round in 2021
Innovative Rehabilitation Equipment Company that Helps Mobility-Impaired Patients to Regain Walking Ability

Inmagene Biopharmaceuticals

Series B in 2020
Inmagene Biopharmaceuticals Co. Ltd. is a Shanghai-based biopharmaceutical company founded in 2019, specializing in the research and pre-clinical development of therapies for immunology-related diseases. The company focuses on creating innovative drug candidates that address unmet medical needs globally, employing a strategy known as "Borderless Innovation." Inmagene has developed a diverse pipeline, including IMG-020, a protein drug designed to target IL-17A, which utilizes a combination of Affibody's protein therapeutics platform and Albumod technology to enhance potency and extend half-life. In addition to IMG-020, the company boasts several clinical-stage assets and multiple preclinical candidates aimed at improving pharmacokinetic and pharmacodynamic properties, safety profiles, and dosing convenience for patients. With additional offices in Hangzhou and Beijing, Inmagene is dedicated to advancing drug development through cutting-edge technology and a commitment to global collaboration in the fight against immunological diseases.

Zhaoke Ophthalmology Pharmaceutical

Series B in 2020
Zhaoke Ophthalmology Pharmaceutical is a Pharmaceutical platform.

XW Laboratories

Series C in 2020
XW Laboratories Inc. is a biopharmaceutical company based in Wuhan, China, specializing in the discovery and development of innovative treatments for neurological disorders. Established in 2014, the company has created three distinctive research and development platforms, including Prodrug and Functional Group Switch, which facilitate the rapid identification of new drug candidates while minimizing development costs and time. XW Laboratories aims to enhance patient compliance and reduce toxicity associated with existing medications. In addition to focusing on the domestic market, the company collaborates with international partners to extend its reach in foreign markets, positioning itself at the forefront of medicinal technology in the Asia-Pacific region.

XWPharma

Series C in 2020
XWPharma is a neuroscience biotechnology company based in the Bay Area, California, focused on developing innovative therapeutics for sleep, neuropsychiatric, and other neglected central nervous system (CNS) disorders. The company specializes in drug discovery and vaccine development, aiming to address underserved conditions that affect patients' mental health and sleep quality. Through its research, XWPharma seeks to create new medications that can help individuals overcome insomnia and related disorders, ultimately improving their overall well-being.

Actym Therapeutics

Series A in 2020
Actym Therapeutics is a biotechnology company based in Berkeley, California, dedicated to developing innovative immuno-oncology therapies for cancer treatment. Founded in 2017, the company has created a unique therapeutic platform known as STACT (S. Typhimurium-Attenuated Cancer Therapy), which uses an attenuated microbial approach to target solid tumors while sparing healthy tissue. This platform allows for the delivery of multiple immuno-modulatory payloads directly to immune cells residing within tumors, addressing challenges faced by traditional therapies. In preclinical studies, STACT has shown promise in enhancing treatment efficacy by engaging various biological pathways from a single therapy. The company successfully secured $34 million in a Series A financing round in April 2020, which was co-led by prominent venture funds, highlighting its potential in the biopharmaceutical landscape.

Human Longevity

Series C in 2019
Human Longevity (HLI) is a genomic-based health intelligence company focused on proactive healthcare and enhancing quality of life. Founded in 2013 and headquartered in San Diego, California, HLI utilizes a comprehensive database of genomic and phenotypic data, combined with advanced machine learning techniques, to drive medical discoveries and transform healthcare practices. The company operates multiple business areas, including the HLI Health Nucleus, a clinical research center that employs whole-genome sequencing, advanced imaging, and curated personal health data to provide an in-depth understanding of individual health. HLI's platform also addresses age-related decline in stem cell function and focuses on major health issues such as cancer, diabetes, obesity, heart and liver diseases, and dementia. By integrating DNA sequencing with expert analysis, HLI aims to empower individuals to take control of their health and shift medical care from a reactive to a proactive approach.

TriArm Therapeutics

Series A in 2019
TriArm Therapeutics is a cell therapy company established by Panacea Venture, with research and development operations in Germany, the United States, and the Greater China region. The company specializes in the research and clinical development of CD19 CAR-T products, utilizing non-viral gene transfer technology. This innovative approach significantly lowers both the cost and preparation time associated with cell therapy products, ultimately aiming to enhance therapeutic outcomes for cancer patients.

Juventas

Series A in 2019
Juventas is a developer of innovative immune cell therapeutic drugs aimed at treating malignant hematological neoplasms, including leukemia and lymphoma. The company has had its first investigational new drug application for the cell therapeutic product CNCT19 accepted by the National Medical Products Administration. Juventas is committed to developing a comprehensive product pipeline that focuses on advancing immune cell therapies and accelerating innovation in this field, thereby providing effective treatment options for patients suffering from these serious conditions.

OncXerna Therapeutics

Series B in 2019
OncXerna Therapeutics, Inc. is a biotechnology company focused on developing precision medicines for cancer patients by utilizing an RNA-based biomarker platform. The company aims to improve patient outcomes by prospectively identifying individuals based on the unique RNA biology of their tumor microenvironments. This innovative approach enables OncXerna to match patients with targeted oncology therapies that correspond to their specific tumor characteristics. Founded in 2018 and based in Waltham, Massachusetts, with an additional location in Shanghai, China, OncXerna was formerly known as Oncologie, Inc. and changed its name in September 2020 to reflect its commitment to advancing next-generation precision medicine for a broader range of cancer patients.

Tactiva Therapeutics

Series A in 2018
Tactiva Therapeutics, LLC is a cancer immunotherapy company based in Buffalo, New York, founded in 2016. The company specializes in developing adoptive cell therapy, utilizing a dual T cell receptor approach to enhance treatment efficacy. Its platform includes engineered CD4 and CD8 T cells that not only provide direct anti-tumor activity but also support the function of CD8 T cell-derived effector cells. This innovative approach aims to create a durable supply of T cells that can effectively target and combat life-threatening cancers, enabling healthcare professionals to improve diagnosis and treatment outcomes for patients.

Evox Therapeutics

Series B in 2018
Evox Therapeutics is a biotechnology company based in Oxford, United Kingdom, founded in 2016. The company specializes in developing exosome-based therapeutics aimed at treating rare and severe diseases. By harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, Evox focuses on creating innovative drug delivery systems that utilize nucleic acids and proteins. This technology allows for targeted delivery to specific organs, including the brain and central nervous system, addressing limitations often encountered with traditional therapies. Evox's proprietary methods for modifying exosomes enhance their ability to transport therapeutic agents effectively, thereby improving treatment options for patients with limited alternatives. The company is supported by a strong intellectual property portfolio and investments from leading life sciences venture capital groups, positioning it as a leader in the emerging field of exosome-based therapeutics.

BioGraph 55

Venture Round in 2018
BioGraph 55 is a biotechnology company specializing in immuno-oncology target discovery and drug development. The firm focuses on creating novel B-cell therapies to address critical unmet clinical needs in oncology and autoimmunity. Its services encompass the discovery and development of bispecific antibodies tailored for immuno-oncology and autoimmunity treatments. BioGraph 55 employs a reverse translational approach to identify potential cellular targets within diseased tissues and validate their mechanisms, enabling scientists to extract clinically relevant insights from the tumor microenvironment.

Atara Biotherapeutics

Atara Biotherapeutics is an off-the-shelf T-cell immunotherapy company based in South San Francisco, California, focused on developing innovative treatments for patients with cancer, autoimmune diseases, and viral infections. The company's lead product, tabelecleucel (tab-cel), is currently in Phase III clinical trials for treating Epstein-Barr virus-associated post-transplant lymphoproliferative disorder, with additional development for other EBV-related hematologic malignancies and solid tumors, such as nasopharyngeal carcinoma. Atara is also advancing next-generation CAR T immunotherapies, addressing various conditions including mesothelin-targeted therapies for solid tumors and treatments for B-cell lymphomas. Other notable candidates include therapies for multiple sclerosis and several viral infections. The company collaborates with esteemed institutions such as Memorial Sloan Kettering Cancer Center and Bayer AG to enhance its research and development efforts. Founded in 2012, Atara Biotherapeutics is committed to transforming the treatment landscape for serious diseases through its robust clinical and scientific initiatives.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.